Skip to main content

Novartis backs hydroxychloroquine trial in COVID-19 fight

Novartis backs hydroxychloroquine trial in COVID-19 fight

Signage is displayed on the exterior of the Novartis AG Institutes for BioMedical Research building in Cambridge, Massachusetts, U.S. PHOTO: Scott Eisen | Bloomberg | Getty Images
Swiss pharmaceutical giant Novartis said Monday it would sponsor a clinical trial in the US using hydroxychloroquine to treat patients hospitalised with COVID-19.
Novartis said it had reached an agreement with the US food and Drug Administration (FDA) to go ahead with a phase III clinical trial with around 440 patients to evaluate whether the drug is efficient in treating coronavirus, which has killed more than 164,000 people worldwide in a matter of months.
The company said its Sandoz division would supply the drugs needed for the trial, which would be conducted at more than a dozen sites in the United States starting within the next few weeks.
Hydroxychloroquine has been used for decades against malaria and is being tested worldwide against the virus along with another anti-malarial drug, chloroquine.
Both have potentially serious side effects, and a range of clinical trials are now underway to determine their efficacy and safety.
“We recognise the importance of answering the scientific question of whether hydroxychloroquine will be beneficial for patients with COVID-19 disease,” John Tsai, Novartis Chief Medical Officer said in the statement.
“We mobilised quickly to address this question in a randomised, double-blind, placebo-controlled study,” he added.
Hydroxychloroquine has shown early promise against COVID-19 in small-scale studies in France and China to reduce virus levels among people badly infected.
US President Donald Trump has touted it as a coronavirus treatment and in the US a limited emergency-use authorisation has been granted to the drug.
But many scientists are urging caution until larger trials show whether it is safe and effective.
Novartis said that patients in its trial would be randomised into three groups, with the first group receiving hydroxychloroquine, the second receiving the drug combined with an antibiotic therapy, and the third group receiving a placebo.
“Researchers at the company compressed months of work into a few weeks to design the large clinical trial in order to rapidly respond to the need for COVID-19 disease treatments,” the company said.
Novartis said it would donate 130 million tablets of hydroxychloroquine to supply global clinical research efforts if the medicine is proven beneficial against COVID-19.
It also said it would open up its intellectual property rights relating to the use of hydroxychloroquine in a bid to facilitate access to the drug if it proves beneficial.
The company said it planned to sponsor or co-sponsor clinical trials to study the benefits of two other drugs, ruxolitinib, which is sold under the brand name Javaki, and canakinumab, commercialised as Ilaris, for patients hospitalised with COVID-19


Comments

Post a Comment

Popular posts from this blog

See how Tinubu reacts to #EndSARS protests, says police reforms has begun

 See how Tinubu reacts to #EndSARS protests, says police reforms has begun National leader of the All Progressives Congress (APC) Bola Tinubu has said the protest against police brutality in Nigeria is within the constitutional right of Nigerians. “Asiwaju Tinubu believes in the right of Nigerians to freedom of expression, assembly, and protest where and when necessary, he has always canvassed the need for people to explore peaceful channels to ventilate their views and demands,” Tinubu said in a statement by his media aide Tunde Rahman. “He believes the #EndSARS protesters have made their demands, which the Federal Government is studying.” Tinubu’s statement comes after being alleged of being one of the sponsors of the ongoing nationwide protest against brutality, extortion, harassment and extrajudicial killing by police personnel. The Cattle’s Breeders Association known as Miyetti Allah had earlier accused Tinubu of using the protest to distort the administration of President Muh...
Post a Comment
Read more

Operators seek tax holiday, subsidy to save airlines

Operators seek tax holiday, subsidy to save airlines Worried by the fate that awaits local carriers, operators yesterday, appealed to the Federal Government to introduce some economic recovery measures to safeguard airlines from collapse.    The operators, currently burdened by recurrent costs, are seeking aviation intervention fund at an interest rate of not more than five per cent. They suggested that government could take a cue from the American model of offering 50 per cent funding and grants, and 50 per cent palliatives through waivers and suspension of taxes, levies and fees among others.     Besides, they called for the implementation of President Muhammadu Buhari’s Executive Order on Removal of Value Added Tax (VAT) from all forms of transportation; as domestic airlines are still the only forms of transportation paying VAT.    The current restriction of both local and foreign commercial flight services has forced domestic carriers into fin...
Post a Comment
Read more

Senate to write Buhari over dead lawmaker on FCC board

Senate to write Buhari over dead lawmaker on FCC board Senate President Ahmad Lawan will draw the attention of President Muhammadu Buhari to the erroneous inclusion of a dead person on the list of nominees sent to the Senate, The Guardian has learnt. It emerged on Wednesday that the list for the appointment of members into the Federal Character Commission (FCC) included the late Tobias Chukwuemeka Okwuru, a former member of the House of Representatives from Ebonyi State. Okwuru, the 12th on the 38-person list died in February 2020, aged 59. Until his demise, he had acted as chairman of the House Committee on Environment and had represented Ikwo/Ezza Federal Constituency between 2011 and 2015. This is, however, not the first time names of the dead have featured in appointments by Buhari since he became president in May 2015. In 2017, the names of five persons said to be dead appeared on a list of appointments onto the boards of federal agencies and corporations. They were:...
Post a Comment
Read more